PRMT5 in gene regulation and hematologic malignancies.

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Biology

Background:

• Arginine methylation is a crucial posttranslational modification regulating cellular processes.
• Protein arginine methyltransferases (PRMTs) catalyze arginine methylation, with PRMT5 being a key type II enzyme.
• PRMT5 mediates symmetric dimethylarginine formation on histones and nonhistone proteins, impacting gene expression and cellular functions.

Purpose of the Study:

• To elucidate the role of PRMT5 in cellular processes and hematologic malignancies.
• To highlight PRMT5's function in gene silencing and cancer cell proliferation.
• To discuss the therapeutic potential of targeting PRMT5 in cancer treatment.

Main Methods:

• Review of existing literature on PRMT5 function and its role in cancer.
• Analysis of PRMT5's enzymatic activity on histone and nonhistone substrates.
• Examination of PRMT5 expression patterns in hematologic malignancies.

Main Results:

• PRMT5 catalyzes symmetric dimethylarginine, leading to gene silencing via repressive histone marks.
• PRMT5 methylates nonhistone proteins, including transcription factors, influencing diverse cellular pathways.
• Elevated PRMT5 expression is observed in leukemia and lymphoma, promoting cancer cell proliferation.

Conclusions:

• PRMT5 plays a significant role in regulating gene expression and promoting cancer cell growth.
• Targeting PRMT5 with inhibitors presents a viable therapeutic avenue for hematologic cancers.
• Further research into PRMT5 inhibition could lead to novel cancer treatments.